Abstract: Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), is a pioneering first-generation histone deacetylase (HDAC) inhibitor that has significantly impacted oncology research. Originally approved by the US Food and Drug Administration (FDA) in 2006 for the treatment of cutaneous T-cell lymphoma (CTCL), SAHA has since been extensively investigated for its therapeutic potential across a wide spectrum of hematological malignancies and solid tumors, including breast cancer, non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and prostate cancer. This comprehensive review synthesizes current literature on SAHA, detailing its broad pharmacological activities, which include the induction of cell cycle arrest, apoptosis, and autophagy, as well as the inhibition of angiogenesis and metastasis. Furthermore, the review explores SAHA's molecular mechanisms, its structure-activity relationships—including the development of novel chimeric inhibitors—and the current clinical limitations such as systemic toxicity and poor oral bioavailability. Finally, future perspectives focusing on synergistic combination therapies and advanced nanocarrier drug delivery systems are discussed as strategies to overcome existing therapeutic barriers and improve patient outcomes.
1. Introduction
Epigenetic dysregulation plays a critical role in tumorigenesis, tumor heterogeneity, and resistance to conventional anti-cancer therapies. Histone deacetylases (HDACs) act as transcriptional repressors by promoting chromatin condensation through the removal of acetyl groups from histone proteins, thereby silencing tumor suppressor genes [2]. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a first-generation, moderately orally bioavailable pan-HDAC inhibitor that targets class I, II, and IV HDAC enzymes [2][9]. By inhibiting these enzymes, SAHA facilitates the hyperacetylation of histones and non-histone proteins, leading to the reactivation of silenced genes and the modulation of various cellular pathways [2]. SAHA was the first HDAC inhibitor to receive FDA approval in 2006 for the treatment of progressive, persistent, or recurrent cutaneous T-cell lymphoma (CTCL) [2][8]. Since its approval, extensive preclinical and clinical research has been dedicated to expanding its application to other malignancies, making it a cornerstone compound in the field of epigenetic oncology research.
2. Pharmacological Activity
SAHA exhibits a diverse array of pharmacological activities across multiple cancer types. In breast cancer, SAHA demonstrates potent anti-proliferative effects in both luminal and triple-negative breast cancer (TNBC) cell lines. It induces dose-dependent apoptosis and triggers G1/G2 cell cycle arrest [2]. Furthermore, SAHA has been shown to inhibit cell migration and suppress epithelial-mesenchymal transition (EMT), a key process in cancer metastasis [2]. In non-small cell lung cancer (NSCLC), SAHA initiates G1/G2 cell-cycle arrest, disrupts vascular endothelial growth factor (VEGF) signaling to hinder tumor neovascularization, and enhances the cytotoxicity of DNA-targeting agents like carboplatin [3]. In hematological malignancies such as acute myeloid leukemia (AML), SAHA induces differentiation, growth arrest, and apoptosis, while also increasing the differentiation induced by retinoic acid in acute promyelocytic leukemia cells [7]. In prostate cancer models, SAHA has been shown to significantly reduce tumor volumes in vivo, although translating this to clinical efficacy has proven challenging [8].
3. Molecular Mechanism of Action
The primary molecular mechanism of SAHA involves its binding to the zinc ion located within the catalytic domain of HDAC enzymes, thereby blocking their activity [2]. This inhibition leads to the accumulation of acetylated histones (e.g., H3K14, H3K27) and non-histone proteins [2]. SAHA specifically targets and reactivates tumor suppressors such as p53 and retinoblastoma protein (Rb1), while simultaneously inactivating AMPK signaling, culminating in apoptosis [1]. In breast cancer, SAHA modulates hormone receptor status; it can deplete estrogen receptor alpha (ERα) at both transcriptional and posttranslational levels via the ubiquitin-proteasome pathway, which is particularly relevant for hormone-refractory cancers [2]. Conversely, it can also re-express ERα and progesterone receptors (PR) in TNBC, sensitizing these aggressive cells to tamoxifen [2]. SAHA also regulates EMT by downregulating the expression and nuclear translocation of forkhead box protein A1 (FOXA1) [2]. Additionally, SAHA induces DNA double-strand breaks, generates reactive oxygen species (ROS), and modulates the expression of pro-apoptotic (Bax, Bim, PUMA) and anti-apoptotic (Bcl-2, Bcl-xL) proteins [2][5][7].
4. Structure-Activity Relationship (SAR)
SAHA belongs to the hydroxamic acid class of HDAC inhibitors [2][3]. Its chemical structure consists of a hydrophobic cap that interacts with the external surface of the enzyme, a linker that transverses the active site channel, and a hydroxamic acid chelating group that coordinates with the zinc ion in the active site [8]. To improve affinity, overcome drug resistance, and target multiple pathways simultaneously, researchers have developed chimeric HDAC-based inhibitors by combining the pharmacophore of SAHA with other anticancer agents. For instance, CUDC-101 is a hybridized molecule combining the hydroxamic acid group of SAHA with the quinazoline core of erlotinib, allowing it to simultaneously inhibit HDAC, EGFR, and HER2 [2]. In leukemia research, NL-101 was synthesized by replacing the side chain of the alkylating agent bendamustine with the hydroxamic acid of SAHA, resulting in a compound that induces both HDAC inhibition and DNA damage [7]. Another example is the piperlongumine-SAHA hybrid inhibitor, which has shown potent antileukemic activities [7].
5. Current Limitations
Despite its success in treating CTCL, SAHA has faced significant limitations in the treatment of solid tumors as a monotherapy [2]. A major pharmacological drawback is its relatively low oral bioavailability and short apparent half-life, which ranges from 91 to 127 minutes [2]. Clinically, SAHA is associated with substantial toxicities that frequently lead to dose reductions or trial terminations. Common adverse events include fatigue, nausea, vomiting, dyspnea, anemia, and severe thrombocytopenia [6]. In a clinical trial for castration-resistant prostate cancer (CRPC), nearly half of the patients had to be removed from the study due to drug-induced toxicities before six months [8]. Interestingly, patients who experienced severe toxicity and had to be removed from the SAHA trials often exhibited higher baseline levels of interleukin-6 (IL-6), suggesting a link between systemic inflammation, drug toxicity, and non-responsiveness [8]. Furthermore, genetic variations, such as the UGT2B17*2 null genotype (common in Asian populations), affect SAHA glucuronidation and metabolism, leading to altered pharmacodynamics and toxicity profiles [2].
6. Future Perspectives
To overcome the limitations of SAHA monotherapy, current research is heavily focused on combination strategies and advanced drug delivery systems. Preclinical and clinical studies have demonstrated that SAHA acts synergistically with a variety of conventional chemotherapeutics and targeted agents. In breast cancer, SAHA enhances the efficacy of cisplatin, paclitaxel, trastuzumab, and PARP inhibitors like olaparib [2][5]. It also sensitizes resistant cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [2][5]. In AML, combinations with decitabine, cytarabine, and aurora kinase inhibitors have shown promising response rates [7]. Additionally, the integration of SAHA with immunotherapy (e.g., pembrolizumab) is being actively explored to reverse immune evasion phenotypes [5][6]. To address pharmacokinetic shortcomings and systemic toxicity, the development of nanocarrier systems is a major future direction. For example, paclitaxel-SAHA co-prodrug nanomicelles (using mPEG2000-PLA1750 as a carrier) have been developed to provide sustained drug release, improve cytotoxicity against drug-resistant cells, and minimize overlapping toxicities [2]. These innovative formulations and rational combination regimens hold significant promise for maximizing the therapeutic index of SAHA in future oncology practice.
